Revitalized Conmed Pushes The Increments In Ortho And Says ‘Innovation Always Wins’
COVID-19 put a dampener on Conmed’s 50th anniversary of operations, but CFO Todd Garner says the company is poised to resume its growth strategy, post-pandemic.
You may also be interested in...
ConMed’s ‘No Smoking’ Drive Has Multiple Benefits In General Surgery
ConMed Corp. is company of two halves ̶ general surgery and orthopedics – and is readying itself for a renewed assault on these two markets on the back of a technology pipeline, targeted acquisitions and a new growth-winning culture, says CFO Todd Garner.
News We’re Watching: Medtronic To Buy EOFLow, Neuralink Cleared For Human Trials, NICE Backs Genetic Tests
This week, Medtronic said it would pay $738m for insulin patch firm EOFlow; Neuralink got an FDA OK for first-in-human trials; and UK agency NICE backed genetic tests for stroke patients and digital therapeutics for mental health conditions.
The E in ESG: Thermo Fisher On Why The ‘How’ Is More Important Than The ‘When’
Life sciences and diagnostics group Thermo Fisher Scientific is encouraging suppliers to meet the same ambitious climate change targets that it has set for itself – mindful that Scope 3 emissions account for the vast majority of industry’s environmental footprint. But the drive for compliance must not compromise achievements made in the “S in ESG,” says corporate VP, CSR and sustainability, Meron Mathias.